HSP90AB1 and neoplasm: In the study conducted on cell models (murine and human), it was shown [106] that the use of HSP90 inhibitors (ganetespib and onalespib) in different CRPC genotypes and phenotypes affects the inhibition of oncogenic cell signaling mechanisms regulating tumor growth and development.